Retatrutide: A Potent GLP-1 Agonist in Clinical Trials | Retatrutide News

Retatrutide, a new GLP-1 agonist by Eli Lilly, is in clinical trials for obesity treatment. This development highlights ongoing advancements in GLP-1 re...
Clinical Trials · October 11, 2026